Based in part upon the representations of the Purchasers in the Securities Purchase Agreement, the offering and sale of the securities issued in the Private Placement is exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws.

Other Events. On July 30, 2026, the Company issued a press release announcing the pricing of Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. 2

Entry into a Material Definitive Agreement On July 30, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell in a private placement offering (the “Private Placement”) an aggregate of (i) 191,571 shares of its common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $1.74 per share a…

Regulation FD Disclosure On July 20, 2026, the Company updated its investor presentation, which it intends to use from time to time in meetings with investors, analysts and other members of the investment community. A copy of the updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18…

Other Events On July 7, 2026, the Company prepared, and as of the date of this notice was preparing for submission to the U.S. Food and Drug Administration (“FDA”), a statistical analysis plan (the “SAP”) for the planned interim analysis of its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis (NCT0627370). The SAP states the following: “An interim analysis will be performed at the earlier of (i) 10/30/26 or (ii) after 24 of the 33 planned pat…

Other Events The Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a New Drug Application submission to the U.S. Food and Drug Administration (“FDA”) before the end of the first quarter of 2028. The Company is providing this disclosure to inform investor…

Director — Eric Francois: The company appointed Eric Francois as a new director to the Board.

Other Events. On March 20, 2026, the Company determined that an error was made in the calculation of the number of shares of common stock beneficially owned by an affiliate of the Company, which was disclosed in the Company’s prospectus supplement dated March 13, 2026 (the “Prospectus Supplement”). Specifically, the number of shares beneficially owned by such affiliate was incorrectly reported as 21,490 shares. The correct number of shares beneficially owned by such affiliate is 23,367 shares…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished pursuant to Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The presentation contains forward-lo…

Entry into a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) pursuant to which the Company may, from time to time, offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $1,397,533 (the “ATM Offering”), through or to Wainw…

Termination of a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) and Wallachbeth Capital LLC (“Wallachbeth”) entered into a Waiver and Termination Agreement of the At-The-Market Issuance Sales Agreement, dated June 4, 2024 (the “ATM Agreement”). The Company and Wallachbeth agreed to waive the 10-day notice termination period (the “Notice Termination Period”), and the Company exercised its right to the immediate termination of the ATM Agree…

Entry into a Material Definitive Agreement. On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) relating to the sale of (i) 1,753,314 share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 878,264 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 878,264 shares of Common Stock, (iii) Series A-1 warran…

Entry into a Material Definitive Agreement. On January 28, 2025, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 1,021,549 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) at a purchase price of $1…

Unregistered Sales of Equity Securities. The disclosures set forth in

Entry into a Material Definitive Agreement On September 4, 2024, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell in a private placement offering (the “Private Placement”) (i) an aggregate of 2,898,551 pre-funded warrants (the “Pre-funded Warrants”), each having the right to purchase one share of common stock, par valu…

Other Events. On September 4, 2024, the Company issued a press release announcing the pricing of Private Placement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. On September 6, 2024, the Company issued a press release announcing the closing of Private Placement. The full text of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. 2

Based in part upon the representations of the Purchaser in the Securities Purchase Agreement, the offering and sale of the securities issued in the Private Placement is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws.

Other Events. On July 25, 2024, 60 Degrees Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it was awarded a contract, valued at $311,862, with the United States Army Medical Materiel Development Activity to facilitate commercial validation of a new bottle and replacement blister packaging of ARAKODA® (tafenoquine), the Company’s U.S. Food and Drug Administration-approved product indicated for malaria prevention. This initiative is critical for ensuring the continu…